Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: A meta-analysis

Gaoyang Gu MS1 | Jing Wu MS2,3 | Xiaofei Gao MS3 | Meijun Liu MS3 | Chaolun Jin MS3 | Yizhou Xu MD1,3

1Department of the Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
2Department of Nursing College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
3Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Correspondence
Yizhou Xu, MD, Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, #261 Huansha Road, Hangzhou 310000, Zhejiang, China.
Email: xyzsci@163.com

Funding information
This work was supported by the Construction Fund of Key Medical Disciplines of Hangzhou, Grant/Award Number: OO20200121

Abstract

Background: Catheter ablation (CA) is an effective treatment for patients with atrial fibrillation (AF). The potential of CA to benefit AF patients with heart failure and preserved ejection fraction (HFpEF) is uncertain.

Hypothesis: CA may be safe and effective for patients with HFpEF.

Methods: The Medline, PubMed, Embase, and Cochrane Library databases were searched for studies evaluating CA for AF patients with HFpEF.

Results: A total of seven trials with 1696 patients were included. Pooled analyses demonstrated similar procedure and fluoroscopy time regarding the use of CA for patients with HFpEF and without HF (weighted mean difference [WMD]: 0.40; 95% confidence interval (CI): −0.01–0.81, \( p = .05 \) and [WMD: 0.05; 95% CI: −0.18–0.28, \( p = .68 \)]). Moreover, CA was effective in maintaining sinus rhythm (SR) in patients with HFpEF and noninferior for patients without HF [risk ratio (RR): 0.92; 95% CI: 0.76–1.10, \( p = .34 \)]. Additionally, CA tended to significantly maintain SR (RR: 4.73; 95% CI: 1.86–12.03, \( p = .001 \)) and reduce rehospitalization for HF compared with medical therapy (RR: 0.36; 95% CI: 0.19–0.71, \( p = .003 \)). However, no significant differences were found between two groups regarding the mortality rate (\( p = .59 \)).

Conclusion: CA is a potential treatment strategy for patients with HFpEF and demonstrates equivalent efficacy to that of patients without HF. Moreover, the benefits of CA in maintaining SR and reducing rehospitalization of HF patients were significantly better than those of medical therapy. Additional randomized controlled trials are warranted to confirm our results.

KEYWORDS
atrial fibrillation, catheter ablation, efficacy, heart failure with preserved ejection fraction, safe
1 | INTRODUCTION

The diagnosis of heart failure with preserved ejection fraction (HFpEF) requires the identification of symptoms or signs of heart failure (HF) and preserved left ventricular ejection fraction (LVEF ≥50%), which accounts for approximately half of HF cases.\(^1\) HFpEF is always associated with left ventricular (LV) diastolic dysfunction, which results in increased LV end-diastolic pressure, followed by increased left atrial (LA) filling pressure and atrial wall pressure, which affects the renin-angiotensin system, calcium handling, profibrotic and proinflammatory pathways, all of which promote electrical and structural remodeling of the atria and contribute to the development of atrial fibrillation (AF).\(^2\)–\(^5\) Therefore, HFpEF and AF frequently coexist and their comorbidity is associated with poor prognosis.\(^6\),\(^7\)

Catheter ablation (CA) is a well-established therapeutic option for AF.\(^8\) HF may increase the risk of CA complications. However, CA has been shown to decrease AF burden and reduce mortality and rehospitalization for AF patients with HF with reduced EF (HFrEF) without causing a significant increase in the incidence of adverse events.\(^9,10\) For patients with HFpEF, Androulakis et al used a single-arm meta-analysis to evaluate the use of CA,\(^11\) in addition, some studies and meta-analysis compared efficacy of CA in AF patients with HFpEF and HFrEF, and showed similar efficacy and safety between two groups.\(^12\)–\(^14\) However, these studies were insufficient to determine the superiority of CA in these populations. Studies comparing efficacy between HFpEF and those without HF are necessary to illustrate the universality of CA in AF patients with HFpEF. Moreover, the jury is still out on whether CA is superior to medical therapy alone in these populations. Recently, certain studies attempted to explore the application of CA in AF patients with HFpEF and those without HF, and compared efficacy between CA and medical treatment, but the results were inconsistent.\(^2\)\(^5\)–\(^20\) Therefore, this meta-analysis was performed to evaluate the clinical benefits of CA for AF patients with HFpEF.

2 | METHODS

2.1 | Data sources and search strategy

Relevant studies were sourced from Medline, PubMed, Embase, the Cochrane Library, and Elsevier’s ScienceDirect databases. The search strategy employed relevant keywords and medical subject heading (MeSH) terms, including the following: [Atrial fibrillation] OR [AF] and [(Radiofrequency) OR [RF] OR [Catheter ablation] OR [ablation]] and [(Heart Failure] OR [HF]) and [(Heart failure with preserved ejection fraction] OR [HFpEF]]. The literature search was updated in January 2022.

2.2 | Inclusion and exclusion criteria

Two reviewers (Gao-yang Gu and Jing Wu) screened and identified studies that met the following inclusion criteria: (a) Patients with drug-refractory symptomatic AF (b) patients with HFpEF; (c) patients undergoing treatment using CA for the first time; (d) sample size ≥20; (e) studies that provided reliable information regarding the outcomes. The exclusion criteria were as follows: (a) Patients with HFrEF; (b) An equivocal study design or group allocation and (c) conference abstracts, case reports, case series studies, editorials, review articles, or non-English language articles.

2.3 | Quality assessment and data extraction

The study quality was evaluated by 2 investigators (Mei-jun Liu and Chao-lun Jin) using the Newcastle-Ottawa Scale (NOS) for observational studies and the Delphi consensus criteria for randomized controlled studies (RCTs). The NOS system consisted of 8 questions with 9 possible points. A star system was used to assess the data according to the selected populations, comparability of the groups, and exposure/outcome of interest. A previous study with NOS ≥7 was considered to be a study of good quality.\(^21\) The Preferred Reporting Items for Systematic Reviews and Meta-analyses Amendment to the Quality of Reporting of Meta-analyses Statement and recommendations from the Cochrane Collaboration in epidemiology were followed. Data extraction was conducted by mutual agreement and all potential disagreements were resolved by consensus.\(^22\)\(^23\)

2.4 | Outcome definitions

Freedom from AF was defined as absence of any symptomatic or asymptomatic atrial arrhythmia lasting >30 s after completing the blanking period (3 months) after CA or medical treatment. Procedure time was defined as the time from the application of local anesthetics to the withdrawal of all catheters. The fluoroscopy time was defined as the time of fluoroscopy from the start to the end of the procedure. Rehospitalization was defined as rehospitalization after discharge due to HF.

2.5 | Statistical analysis

Statistical analysis was performed by an independent statistician (Jing Wu). Odds ratios (ORs) or risk ratios (RRs) with 95% confidence intervals (CIs) were used as risk estimates and were pooled by the software. Continuous variables were analyzed using weighted mean differences (WMD). Between study heterogeneity was reflected by \(I^2 > 50\). A \(p < .05\) was considered to indicate a statistically significant difference. In case of no significant statistical heterogeneity, the fixed effects model was preferentially used as the summary measure. In case of statistical heterogeneity, sensitivity analyses were performed to assess the contribution of each study to the pooled estimate by sequentially excluding the individual trial time period and recalculating the pooled RR estimate for the remaining studies. All statistical analyses were performed using RevMan version 5.3 (Nordic Cochrane Center; The Cochrane Collaboration, 2014).
### Results

#### 3.1 Study and data selection

The flowchart of the detailed search process is illustrated in Figure 1. Initially, 317 potential studies were identified, of which 59 were duplicates and 189 were excluded following review of the titles and abstracts. Of the remaining 69 studies, 18 review articles, 11 abstracts, 5 editorial/letters, and 3 case reports were excluded. Furthermore, 25 studies were excluded following a detailed evaluation of the full text for the following reasons: A total of 8 were uncontrolled studies, 4 were clinical study designs, 10 lacked study endpoints, and 3 reported duplicate data. Consequently, 7 clinical trials with 1696 patients were enrolled in the current meta-analysis.

#### 3.2 Study characteristics

The characteristics of the included trials are shown in Table 1. A total of seven trials with 1696 patients were included. Four of these studies compared the clinical outcomes following AF ablation in patients with HFpEF and without HF, whereas the other 3 studies investigated the clinical outcomes of HFpEF patients with AF treated either by CA for AF or medical therapy. The mean age of the study participants ranged from 64 ± 12 years to 74 ± 7 years, and the mean follow-up duration was from 12 to 50.9 months. The percentage of men was 44%–87.2%. The percentage range of paroxysmal AF was 38%–77%. The majority of the trials included patients that were matched on age, gender, body mass index, and left atrium diameter between the two groups. All studies were rated as having optimal methodological quality. The results of the grouping ensured the feasibility of this meta-analysis.

#### 3.3 CA therapy for patients with HFpEF versus without HF

The pooled analysis demonstrated that HFpEF did not increase the procedure and fluoroscopic time for AF ablation compared with those of patients without HF ([WMD: 0.40; 95% CI: −0.01–0.81, p = .05; I² = 67%] and [WMD: 0.05; 95% CI: −0.18–0.28, p = .68; I² = 0%]; Figure 2A,B). Moreover, the rate of freedom from AF was also similar between patients with HFpEF and without HF (RR: 0.92; 95% CI: 0.76–1.10, p = .34; I² = 75%; Figure 3A).

#### 3.4 CA versus medical therapy for patients with HFpEF

In general, CA can significantly improve the rate of freedom from AF (RR: 4.73; 95% CI: 1.86–12.03, p = .001; I² = 82%; Figure 3B) compared with that of medical therapy. In addition, CA therapy can reduce the rate of rehospitalization due to HF (RR: 0.36; 95% CI: 0.19–0.71, p = .003; I² = 40%; Figure 4A). However, no significant differences were observed following the comparison of CA with medical therapy with regard to the all-cause mortality rate (RR: 0.58; 95% CI: 0.08–4.25, p = .59; I² = 53%; Figure 4B).

### Discussion

The major findings of the present study are as follows: (a) Patients with HFpEF can benefit from CA compareable with patients without HF with similar procedure and fluoroscopic time and a similar rate of freedom from AF. (b) CA can significantly improve the rate of freedom from AF and the rate of rehospitalization due to HF, while it exhibits a similar rate of all-cause mortality compared with medical therapy.

HFpEF in patients suffering from AF is associated with increased symptoms and higher morbidity, mortality, and rehospitalization for HF. It has been reported that the prevalence of AF ranges from 30% to 65% for patients with HFpEF. Zakeri et al. revealed that 2/3 of HFpEF patients would suffer from AF in the disease natural history, which is associated with increased death and HF rehospitalization. Another study by Nagai et al. demonstrated that AF was a key factor affecting HFpEF development and rehospitalization. Diastolic dysfunction is a hallmark of HFpEF, which leads to intolerance of tachycardia. This accounts for the detrimental effects noted in these patients. Therefore, certain additional therapeutic strategies that focus on AF are necessary for the treatment of HFpEF patients with AF. The CA of AF in HFrEF patients has been shown to effectively maintain sinus rhythm (SR), improve heart function, and reduce hospitalization and mortality. To explore the efficacy of CA in AF patients with HFpEF, Androulakis et al. included several studies on the use of CA in AF patients with HFpEF and conducted a single-arm meta-analysis. The results showed that CA can be useful to maintain SR. However, as a single-arm meta-analysis, it has some limitations, such as the lack of control group and the significant heterogeneity. In addition, some other studies and meta-analyses compared the efficacy of CA between HFpEF and HFrEF, and identified similar efficacy between two groups. These studies tried to explore the
| Trial (year) | Treatment group | Patients (n) | Age (y) | Male (n, %) | BMI (kg/m²) | Paroxysmal (n, %) | CHA2DS2-VASc | Echocardiographic parameters | Co-morbidities | Follow (M) | Design | NOS |
|-------------|----------------|--------------|---------|-------------|-------------|------------------|-------------|------------------|---------------|-----------|--------|-----|
| Cha et al. (2011) | HFpEF + Ablation | 157 | 62.2 (54.4, 70.5) | 107 (68) | NR | 78 (50) | NR | 40 (35, 50) | 62 (60, 65) | 75 (48) | 15 (10) | 8 (5) | 27 (17) | 12 | Prospective | 9 |
| No HF + Ablation | 100 | 52.8 (43.9, 59.7) | 75 (75) | NR | 61 (61) | NR | 25 (22, 28) | 63 (60, 65) | 29 (29) | 5 (5) | 4 (4) | 15 (15) | |
| Aldaas et al. (2020) | HFpEF + Ablation | 51 | 67.6 (56.6, 74.7) | 31 (60.8) | 29.7 | 25 (49) | 3.0 (2.0, 4.0) | 4.2 (3.9, 4.9) | 58 (52, 65) | 38 (75) | 8 (16) | 5 (10) | 19 (37) | 50.9 (24.5, 62.3) | Retrospective | 8 |
| No HF + Ablation | 456 | 64.3 (57.6, 70.5) | 307 (67.3) | 27.8 | 331 (74) | 2.0 (1.0, 3.0) | 4.0 (3.7, 4.5) | 64 (60, 68) | 243 (53) | 44 (10) | 38 (8) | 51 (11) | 31.3 (9.2, 57.3) | |
| Rattka et al. (2020) | HFpEF + Ablation | 35 | 69 ± 9 | 14 (40) | 29 ± 6 | 27 (77.1) | NR | NR | NR | 28 (80.0) | 5 (14.3) | 2 (5.7) | 13 (37.1) | 29 ± 20 | Retrospective | 7 |
| No HF + Ablation | 150 | 64 ± 12 | 87 (58) | 28 ± 5 | 105 (70.0) | NR | NR | NR | 115 (76.7) | 18 (12.0) | 14 (9.3) | 51 (34.0) | |
| Yamauchi et al. (2021) | HFpEF + Ablation | 293 | 69.6 ± 7.9 | 196 (66.9) | 24.4 ± 3.9 | 61 (48.8) | 2.80 ± 1.50 | 43.5 ± 5.7 | 63.0 ± 6.4 | 190 (64.8) | 64 (21.8) | 23 (7.8) | 31 (10.6) | 12 | Retrospective | 9 |
| No HF + Ablation | 125 | 64.2 ± 9.8 | 109 (87.2) | 25.2 ± 3.6 | 189 (64.7) | 1.76 ± 1.43 | 42.3 ± 6.0 | 62.8 ± 5.5 | 66 (52.8) | 23 (18.4) | 7 (5.6) | 11 (8.8) | |
| Rattka et al. (2021) | HFpEF + Ablation | 43 | 73 ± 7 | 19 (44) | 28 (26, 30) | 26 (60) | 4 (3.5) | 46.7 ± 7.4 | 65.3 (55.0, 68.0) | 39 (91) | 10 (23) | 7 (16) | 28 (65) | 35 ± 22 | Case-control | 8 |
| HFpEF + Medical | 43 | 74 ± 7 | 19 (44) | 29 (25, 31) | 22 (51) | 4 (3.5) | 48.2 ± 7.5 | 65.6 (58.6, 72.2) | 39 (91) | 11 (26) | 2 (5) | 27 (63) | |
| Fukui et al. (2020) | HFpEF + Ablation | 35 | 70 ± 8 | 23 (66) | NR | 14 (40) | NR | 42 ± 6 | 62 ± 8 | 21 (55) | 8 (21) | NA | 1 (3) | 703 ± 424 | Retrospective | 8 |
| HFpEF + Medical | 50 | 71 ± 13 | 32 (64) | NR | 19 (38) | NR | 43 ± 6 | 61 ± 9 | 32 (46) | 20 (29) | NA | 6 (12) | |
| Machino-Ohtsuka et al. (2019) | HFpEF + Ablation | 79 | 68 ± 7 | 47 (59.5) | 246 ± 4.2 | NA | 3.9 ± 1.3 | 51 ± 21 | 65 ± 8 | 59 (74.7) | 27 (34.1) | 13 (16.5) | 10 (12.7) | 24 (12.36) | Retrospective | 9 |
| HFpEF + Medical | 79 | 68 ± 9 | 49 (62) | 243 ± 4.3 | NA | 4.0 ± 1.5 | 51 ± 21 | 65 ± 8 | 62 (78.5) | 30 (38.0) | 14 (17.7) | 10 (12.7) | 24 (11.37) | |

Note: Values are reported as the mean ± SD, medians (interquartile range), or n (%). Abbreviations: BMI, body mass index; CAD, coronary artery disease; d, day; DM, diabetes mellitus; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HY, hypertension; LA, left atrium, LVEF, left ventricular ejection fraction; M, month; NOS, Newcastle-Ottawa Quality Assessment Scale; NR, not recorded; Pri-CVA, prior cerebral vascular accident; Y, year.

*a*Evaluate left atrial by LA volume index (cm²/m²).

*b*Evaluate left atrial by left atrial volume (cm³).
clinical benefits of CA in these patients, but were clearly insufficient to demonstrate the universality of CA in AF patients with HFpEF. To further evaluate the role of CA in AF patients with HFpEF, studies comparing efficacy of CA in AF patients with HFpEF and those without HF are warranted, and studies comparing CA with medication are also necessary. Although some studies have carried out related explorations, due to the limitations of the number of studies, sample size, study types (observational studies, retrospective studies) and results inconsistent etc, the level of evidence-based is still insufficient.2,15–20 These issues prompted us to conduct this meta-analysis.

It has been reported that the procedure and fluoroscopic time in patients with HF are significantly longer than those without HF. Substrate remodeling and enlargement of LA may be some of the important reasons.17,28 However, our analysis identified similar procedure and fluoroscopic time periods for patients with HFpEF compared with those without HF, which was in agreement with previous studies.17,18 The reasons may be as follows: (a) according to the baseline data of included studies, patients with HFpEF did not experience significant enlargement of the LA when compared with patients without HF; (b) patients with HFpEF are less likely to develop irreversible and severe fibrosis in the LA29; (c) patients with HFpEF are not accompanied by a significant

---

**FIGURE 2** Forest plots of procedural time (A) and fluoroscopy time (B) regarding the use of CA for patients with HFpEF and without HF. CA, catheter ablation; HFpEF, heart failure with preserved ejection fraction

**FIGURE 3** Forest plots of freedom from AF: CA for patients with HFpEF and without HF (A), CA therapy and medical therapy for patients with HFpEF (B). AF, atrial fibrillation; CA, catheter ablation; HFpEF, heart failure with preserved ejection fraction
decrease in LVEF and fewer emergencies that occurred during procedure. The aforementioned factors may contribute to the nonsignificant differences in the procedure and fluoroscopic time observed for patients with HFP EF and without HF. Moreover, CA of AF can be performed safely in HFP EF, with incidence of complications as low as patients without HF.2,17,18 Numerous studies have demonstrated that CA can effectively maintain SR for patients without HF compared with medical therapy.30–32 In addition, an accumulated number of studies have recently shown that CA can effectively maintain SR in patients with HF compared with antiarrhythmic drugs.9,10,33 Rattka et al.16 demonstrated that even with much stricter rhythm monitoring in patients undergoing CA than patients who were on medical therapy, these patients still exhibited significantly lower rates of AF recurrence. Similar results were obtained in our analysis and the data indicated that CA could reduce the recurrence of AF compared with medical therapy alone. In addition, CA could maintain SR to 80% at 1-year follow-up in patients with HFP EF who received pulmonary vein isolation, which was similar to the results of the patients without HF.18 Pooled analysis of three studies comparing CA in patients with HFP EF and without HF indicated that CA was effective in maintaining SR and noninferior to patients without HF. The main reason may be that the LA in patients with HFP EF did not exhibit severe remodeling, whereas CA for patients with HFP EF even could reverse LA remodeling.16

The maintenance of SR is one of the important factors required to reduce HF rehospitalization, regardless of the type of HF.34–36 CA has been shown to maintain SR effectively, which subsequently leads to a reduction of re-hospitalizations for HF and reduced mortality in patients with HFrEF.10 Machino-Ohtsuka et al.24 reported that CA could maintain SR effectively and that it was associated with a lower risk of HF rehospitalization in patients with HFP EF. Moreover, following a 792 ± 485 day follow-up, 9% and 48% patients in the CA therapy and medical therapy groups exhibited rehospitalization for HF (p < .001).20 Pooled analysis of the included studies indicated a significantly lower risk of rehospitalization for HF in the CA therapy group compared with that of the medical therapy group. However, no significant differences were identified between the CA therapy and medical therapy groups with regard to the all-cause mortality rate.

4.1 | Limitation

Our study exhibits several limitations. First, publication bias could not be completely excluded and the inclusion of only published data contributed to bias. Second, separate data of paroxysmal (PAF) and persistent AF (PerAF) were not provided in the included studies, so subgroup analyses of PAF and PerAF could not be performed; Third, ablation protocols are not fully consistent across studies, which may bias the results; Fourth, the application of anti-HF and antiarrhythmic drugs inevitably varies among patients after procedure, which may affect outcomes, Finally, the number of included studies was limited, and most of them were designed as nonrandomized trials. Therefore, more well-designed and large-scale RCTs are required to confirm these findings.

5 | CONCLUSIONS

The current analysis demonstrated that CA is an efficient, safe, and effective therapeutic approach for AF patients with HFP EF. Similar procedure and fluoroscopic time periods were identified regarding the use of CA for patients with HFP EF and without HF. The success rate of maintaining SR in patients with HFP EF was noninferior to those without HF and was significantly better than that of the medical therapy alone.
group. In addition, CA can reduce rehospitalization due to HF. However, additional multicenter RCTs are required to confirm these results.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

AUTHOR CONTRIBUTIONS
Gaoyang Gu and Jing Wu: contributed to design of this work, statistical analysis and write the manuscript. Mei-jun Liu and Chao-lun Jin: contributed to evaluate quality and retrieved the required data. Xiao-fei Gao: contributed to reviewed the literature, performed the selection of the studies and helped gather references for the manuscript. Yi-zhou Xu: contributed to design of this work, revised and approved the final version of the manuscript.

ACKNOWLEDGMENT
This work was supported by the Construction Fund of Key Medical Disciplines of Hangzhou (No. OO20200121).

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

REFERENCES
1. Ponikowski P, Voors AA, Anker SD, et al. esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (esc) developed with the special contribution of the heart failure association (hfa) of the esc. Eur Heart J. 2016;37(27):2129-2200.
2. Aldaas OM, Malladi CL, Mylavarapu PS, et al. Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction. Am J Cardiol. 2020;136:62-70.
3. Mayyas F, Niebauer M, Zurick A, et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol. 2010;3:369-379.
4. De Jong AM, Maass AH, Oberdorf-Maass SU, Van Veldhuisen DJ, Van Gilst WH, Van Gelder IC. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. 2011;89:754-765.
5. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2016;13:131-147.
6. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved vs. reduced ejection fraction. Circulation. 2016;133:484-492.
7. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013;128:1085-1093.
8. Kuck KH, Brugada J, Finkmranz A, et al. Cryoballoon or radio-frequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235-2245.
9. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA Trial. Circulation. 2021;143(14):1377-1390.
10. Marrouche NF, Brachmann J, Andresen D, et al. CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427.
11. Androuakis E, Sohrabi C, Briasoulis A, et al. Catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Clin Med. 2022;11(2):288.
12. Black-Maier E, Ren X, Steinberg BA, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2018;15(5):651-657.
13. Eitel C, Ince H, Brachmann J, et al. Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. Clin Res Cardiol. 2019;108(7):815-823.
14. Aldaas OM, Lupercio F, Darden D, et al. Meta-analysis of the usefulness of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021;142:66-73.
15. Cha YM, Wokhlu A, Asirvatham SJ, et al. Success of ablation for atrial fibrillation in isolated left ventricular diastolic dysfunction: a comparison to systolic dysfunction and normal ventricular function. Circ Arrhythm Electrophysiol. 2011;4(5):724-732.
16. Rattka M, Kühberger A, Pott A, et al. Catheter ablation for atrial fibrillation in HFpEF patients-A propensity-score-matched analysis. J Cardiovasc Electrophysiol. 2021;32(9):2357-2367.
17. Yamauchi R, Morishima I, Okumura K, et al. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide. Europace. 2021;23(8):1252-1261.
18. Rattka M, Pott A, Kühberger A, et al. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. Europace. 2020;22(9):1328-1336.
19. Kelly JP, DeVore AD, Wu J, et al. Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure. J Am Heart Assoc. 2019;8(24):e011560.
20. Fukui A, Tanino T, Yamaguchi T, et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction. J Cardiovasc Electrophysiol. 2020;31(3):682-688.
21. Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of observational studies in epidemiology (moose) group. JAMA. 2000;283:2008-2012.
23. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the quorom statement. Onkologie. 2000;23:597-602.
24. Machino YT, Ohtsuka T, Seo Y, Ishizu T, et al. Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Cardiovasc Electrophysiol. 2010;31(3):682-688.
25. Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, midrange, and preserved ejection fraction. J Cardiovasc Electrophysiol. 2020;31(3):682-688.
26. Nagai T, Yoshikawa T, Saito Y, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction—A report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPERS) Registry. Circ J. 2018;82:1534-1545.
27. January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. *Circulation*. 2014; 2014(130):2071-2104.

28. Jayanna MB, Mohsen A, Inampudi C, Alvarez P, Giudici MC, Briasoulis A. Procedural Outcomes of Patients With Heart Failure Undergoing Catheter Ablation of Atrial Fibrillation. *Am J Ther*. 2019; 26(3):e333-e338.

29. Zhang L, Xu RL, Liu SX, Dong SH, Zhao XX, Zhang BL. Diagnostic value of circulating microRNA-19b in heart failure. *Eur J Clin Invest*. 2020;50(11):e13308.

30. Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. *JAMA*. 2019;321(11):1059-1068.

31. Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). *Europace*. 2021;23(3):362-369.

32. Su WW, Reddy VY, Bhasin K, et al. Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: Results from the multicenter STOP Persistent AF trial. *Heart Rhythm*. 2020;17(11):1841-1847.

33. Arora S, Jaswaney R, Jani C, et al. Catheter ablation for atrial fibrillation in patients with concurrent heart failure. *Am J Cardiol*. 2020;137:45-54.

34. Shiga T, Suzuki A, Haruta S, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. *ESC Heart Fail*. 2019;6(3):475-486.

35. Fujimoto H, Doi N, Okayama S, et al. Long-term prognosis of patients undergoing radiofrequency catheter ablation for atrial fibrillation: comparison between heart failure subtypes based on left ventricular ejection fraction. *Europace*. 2021:euab201.

36. Cikes M, Claggett B, Shah AM, et al. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. *JACC Heart Fail*. 2018;6(8):689-697.

**How to cite this article:** Gu G, Wu J, Gao X, Liu M, Jin C, Xu Y. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction: A meta-analysis. *Clin Cardiol*. 2022;45:786-793. [doi:10.1002/clc.23841]